RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $24.00 price target on Karyopharm Therapeutics (NASDAQ: KPTI) after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE